CDK13 and neoplasm: We, thus, depleted Cdk12, Cdk13, or both in tumor cells with siRNAs and assessed R-loops with the S9.6 antibody (30, 31), the specificity of which was confirmed using RNase H treatment (Figure 2G and Supplemental Figure 4D).